International immunopharmacology · 2025
Natural drug-derived carbon dots as a novel oral dosing strategy for gouty arthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Ying, Ma Jinyu, Zou Peng, Xia Minlong, Wang Siqi, Jin Bilin, Lu Zixuan, Zhai Changming, Huang Herui, Zhang Yue, Kong Hui, Qu Huihua, Zhao Yan
Аннотация
BACKGROUND: Gouty arthritis (GA), an acute inflammatory disorder triggered by monosodium urate (MSU) crystal deposition, poses a significant global health challenge due to rising prevalence and limitations of current therapies, including single-target mechanisms and adverse effects. The newly synthesized carbon dots (CDs) via high-temperature processing exhibit improved therapeutic efficacy and reduced toxicity.
METHODS: Aconitum Lateralis Radix Praeparata Carbonis-derived Carbon Dots (ALRPC-CDs) were synthesized through a high-temperature carbonization method (400 °C) and characterized by transmission electron microscopy (TEM), high-resolution TEM (HRTEM), ultraviolet-visible (UV-Vis) spectroscopy, fluorescence (FL) spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, X-ray photoelectron spectroscopy (XPS), X-ray diffraction (XRD), and high-performance liquid chromatography (HPLC). Pharmacodynamic assessments included hot-plate analgesia tests, xylene-induced ear edema assays, monosodium urate (MSU)-induced gouty arthritis models, and oxonate potassium/hypoxanthine-induced hyperuricemic models. Biocompatibility was systematically evaluated in LO2 hepatocytes and 293 T renal cells using cell counting kit-8 (CCK-8) assays.
RESULTS: ALRPC-CDs exhibited monodisperse spherical morphology (1.78 ± 0.42 nm) with graphitic lattice structures (d-spacing 0.212 nm), displaying excitation/emission maxima at 314/417 nm. Pharmacodynamic studies revealed their multi-mechanistic therapeutic effects, including robust suppression of the TLR2/4-MyD88-NF-κB pathway, inhibition of xanthine oxidase activity, and significant urate-lowering effects, alongside anti-inflammatory, analgesic, and anti-hyperuricemic activity comparable to clinical controls. Biocompatibility was confirmed with excellent safety profiles.
CONCLUSION: This study demonstrates that ALRPC-CDs alleviate gouty arthritis through dual suppression of inflammatory signaling (TLR2/4-MyD88-NF-κB) and uric acid metabolism (xanthine oxidase inhibition), bridging herbal medicine and nanotechnology for multi-target therapeutic development.
METHODS: Aconitum Lateralis Radix Praeparata Carbonis-derived Carbon Dots (ALRPC-CDs) were synthesized through a high-temperature carbonization method (400 °C) and characterized by transmission electron microscopy (TEM), high-resolution TEM (HRTEM), ultraviolet-visible (UV-Vis) spectroscopy, fluorescence (FL) spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, X-ray photoelectron spectroscopy (XPS), X-ray diffraction (XRD), and high-performance liquid chromatography (HPLC). Pharmacodynamic assessments included hot-plate analgesia tests, xylene-induced ear edema assays, monosodium urate (MSU)-induced gouty arthritis models, and oxonate potassium/hypoxanthine-induced hyperuricemic models. Biocompatibility was systematically evaluated in LO2 hepatocytes and 293 T renal cells using cell counting kit-8 (CCK-8) assays.
RESULTS: ALRPC-CDs exhibited monodisperse spherical morphology (1.78 ± 0.42 nm) with graphitic lattice structures (d-spacing 0.212 nm), displaying excitation/emission maxima at 314/417 nm. Pharmacodynamic studies revealed their multi-mechanistic therapeutic effects, including robust suppression of the TLR2/4-MyD88-NF-κB pathway, inhibition of xanthine oxidase activity, and significant urate-lowering effects, alongside anti-inflammatory, analgesic, and anti-hyperuricemic activity comparable to clinical controls. Biocompatibility was confirmed with excellent safety profiles.
CONCLUSION: This study demonstrates that ALRPC-CDs alleviate gouty arthritis through dual suppression of inflammatory signaling (TLR2/4-MyD88-NF-κB) and uric acid metabolism (xanthine oxidase inhibition), bridging herbal medicine and nanotechnology for multi-target therapeutic development.